Common Contracts

] Shares AIRSCULPT TECHNOLOGIES, INC. COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENT October [ ], 2021

Underwriting Agreement • October 27th, 2021 • Airsculpt Technologies, Inc. • Services-offices & clinics of doctors of medicine • New York

• Contract Type
  Underwriting Agreement
• Filed
  October 27th, 2021
• Company
  Airsculpt Technologies, Inc.
• Industry
  Services-offices & clinics of doctors of medicine
• Jurisdiction
  New York

The undersigned understands that Morgan Stanley & Co. LLC (“Morgan Stanley”), Piper Sandler & Co., and SVB Leerink LLC (together, the “Representatives”) proposes to enter into an Underwriting Agreement (the “Underwriting Agreement”) with AirSculpt Technologies, Inc., a Delaware corporation (the “Company”), providing for the public offering (the “Public Offering”) by the several Underwriters, including the Representatives (the “Underwriters”), of [●] shares (the “Shares”) of the common stock, par value $0.001 per share of the Company (the “Common Stock”).

2,855,000 Shares TFF PHARMACEUTICALS, INC. COMMON STOCK PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENT March 26, 2021

Underwriting Agreement • March 26th, 2021 • TFF Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

• Contract Type
  Underwriting Agreement
• Filed
  March 26th, 2021
• Company
  TFF Pharmaceuticals, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

TFF Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”), for whom Roth Capital Partners, LLC (the “Representative”) is acting as Representative, an aggregate of 2,140,000 shares of common stock, par value $0.001 per share, of the Company (the “Company Shares”). Lung Therapeutics, Inc., a Texas corporation (the “Selling Stockholder”) proposes to sell to the Underwriters an aggregate of 715,000 shares of common stock, par value $0.001 per share, of the Company (the “Stockholder Shares” and together with the Company Shares, the “Shares”). The Company and the Selling Stockholder are hereinafter sometimes collectively referred to as the “Sellers.” The shares of common stock, par value $0.001 per share, of the Company to be outstanding after giving effect to the sales contemplated hereby are hereinafter referred to as the “Common Stock.”